The gastrointestinal system is one of the many organs in the body that have been affected by the new viral illness known as coronavirus disease 2019 (COVID-19). To find out the GIT symptoms are into patients with Covid-19 and how they correspond with the severity of the illness. At the Al-Shifaa facility, 172 patients infected with COVID-19 participated in our study. A clinical examination, laboratory tests (CRP, D.Dimer, and serum ferritin), a chest CT scan, and a medical history were performed on each patient. The severity of the illness and other factors were taken into consideration while evaluating the gastrointestinal symptoms. Data collection from 172 patients, 91 patients infected with COVID-19 infection, 91 patients (52.9%) had GIT manifestation, while 81 patients (47.1%) had without GIT manifestation. According to the severity 117 patients had severe infection of them 60 patients (51.3%) had GIT manifestation and 57 patients (48.7%) without GIT manifestation; 31 patients had moderate infection 20 patients (64.5%) of them had GIT manifestation, and 11 patients (35.5%) without, 24 patients had mild infection 11 patients (45.8%) had GIT manifestation, and 13 patients( 54.2%) without. According to gender, 82 patients( 47.7%) were female (50 patients (61.0%) had GIT manifestation and 32 patients (39.9%) without), 90 patients (52.3%) were male (41 patients (45.65%) had GIT manifestation and 49 patients (54.4%) without). By comparison of inflammatory markers (in the form of CRP titer, D.Dimer, and sr. ferritin ) which were 99.21 ± 13.71, 2.13 ±0.28, and 642.66±49.95 respectively, in those with SARS-CoV-2 infection and 83.37±8.69, 2.19±0.34 and 606±58.57, respectively, for those with no GIT symptoms (p-value =0.34, 0.89, and 0.62, respectively). GIT manifestations are common symptoms in patients with COVID-19. The incidence of GIT manifestations is not affected by the disease severity in SARS-CoV-2 infection. Inflammatory markers (in the form of CRP titer, ferritin, and D-dimer) are not related to the incidence of GIT manifestations in COVID–19 infection.
Background: The gene responsible for encoding the protein of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has been found to be associated with rheumatoid arthritis (RA) in different ethnic populations. But the association of +49A/G CTLA-4 polymorphism with susceptibility of RA among Iraqi Arab populations has not yet been determined. Methods: One hundred and seventy-eight patients were examined, 67 of them were males (mean age 54.71 ± 10.4 years), while 167 were examined for the control group, of whom 64 were males and the rest were females. CTLA-4 DNA genotyping was carried on to determine the +49 A/G (rs231775) polymorphism using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Enzyme-linked immuno
... Show More
(10)
(5)
KE Sharquie, AA Al-Bayatti, AI Al-Ajeel, AJ Al-Bahar, AA Al-Nuaimy, Saudi medical journal, 2007 - Cited by 63
(17)
(31)
(24)
(13)
(12)
(13)
(12)
Non-alcoholic fatty liver disease (NAFLD) is one of chronic liver and defines by fat accumulation ≥5% in liver which can progresses to non-alcoholic steatohepatitis (NASH). NAFLD related to obesity as well as non obese individuals. Adiponectin is a cytokine secreted from adipose tissue involved NAFLD pathogenesis and liked with obesity. Irisin is a myokine, has a convenient effect against metabolic diseases such as obesity, disylipemia diabetes type 2 and reversed liver steatosis and may be related with NAFLD. Vitamin D is one of the fat soluble vitamins and more precisely as a pro-hormone through its metabolite (1,25(OH)2 cholecalciferol) the major steroid hormone. After the skin exposure to the light, vitamin D undergoes to
... Show More
(1)
Abnormalities in the Lipid and lipoprotein levels are common in the general population and are considered as very important risk- factors for cardiovascular disease .In this context the effect of cholesterol, which is one of the most clinically relevant lipids is very important. Aim of the present study was to determine the levels of GLP-1 and GPCR in non- diabetic dyslipidaemic patients and compare the results with the control group, which may be used as a novel biomarker to predict heart disease in these patients. The study was also aimed to find the relationship between GLP-1 and GPCR with lipid profile and glucagon in the patient group. The study involved 90 non-diabetic dyslipidaemia patients, with 90 healthy controls. The subjects wer
... Show More